- Home
- RNTX vs DYAI Comparison
RNTX vs DYAI Comparison
Compare RNTX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- DYAI
- Stock Information
- Founded
- RNTX 2001
- DYAI 1979
- Country
- RNTX United States
- DYAI United States
- Employees
- RNTX N/A
- DYAI N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNTX Health Care
- DYAI Health Care
- Exchange
- RNTX Nasdaq
- DYAI Nasdaq
- Market Cap
- RNTX 28.0M
- DYAI 30.2M
- IPO Year
- RNTX N/A
- DYAI 2004
- Fundamental
- Price
- RNTX $1.15
- DYAI $1.00
- Analyst Decision
- RNTX Hold
- DYAI Strong Buy
- Analyst Count
- RNTX 1
- DYAI 1
- Target Price
- RNTX N/A
- DYAI $6.00
- AVG Volume (30 Days)
- RNTX 133.3K
- DYAI 124.5K
- Earning Date
- RNTX 11-13-2025
- DYAI 11-11-2025
- Dividend Yield
- RNTX N/A
- DYAI N/A
- EPS Growth
- RNTX N/A
- DYAI N/A
- EPS
- RNTX N/A
- DYAI N/A
- Revenue
- RNTX N/A
- DYAI $4,135,078.00
- Revenue This Year
- RNTX N/A
- DYAI $34.23
- Revenue Next Year
- RNTX N/A
- DYAI $19.57
- P/E Ratio
- RNTX N/A
- DYAI N/A
- Revenue Growth
- RNTX N/A
- DYAI 129.20
- 52 Week Low
- RNTX $1.04
- DYAI $0.71
- 52 Week High
- RNTX $4.40
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- RNTX 45.62
- DYAI 58.46
- Support Level
- RNTX $1.07
- DYAI $0.94
- Resistance Level
- RNTX $1.25
- DYAI $1.01
- Average True Range (ATR)
- RNTX 0.14
- DYAI 0.05
- MACD
- RNTX -0.01
- DYAI 0.01
- Stochastic Oscillator
- RNTX 21.33
- DYAI 58.82
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.